Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

C4 Therapeutics, Inc.

Yvonne Alice Nagel

Bernd Kuhn

Roger David Norcross

Georg Jaeschke

Antonio Ricci

Daniel Rueher

Sandra Steiner

Martin Duplessis

Yanke Liang

Kiel Lazarski

Annick Goergler

Cosimo Dolente

David Hewings

Christa Ulrike Obst-sander

Ulrike Obst Sander

Buelent Kocer

Christa Ulrike Obst-Sander

The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.

EGFR inhibitors for the treatment of cancer

The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.

EGFR inhibitor for the treatment of cancer

The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancers

The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds

The present invention provides substituted isoindole compounds which are selective allosteric EGFR inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, generally of Formula: or a pharmaceutically acceptable salt thereof.

Substituted isoindole allosteric EGFR inhibitors

Growing community of inventors

Basel, Switzerland

Yvonne Alice Nagel